Insights

The Shift Toward Western Pharmaceutical Manufacturing: Considerations in Attaining the Right Global Mix

icons/content-types/white paper white paper

General

The COVID-19 pandemic has brought the global interdependency of pharmaceutical supply chains into sharp focus, exposing weak links and re-igniting discussions around the value of reshoring production. The U.S. Food and Drug Administration (FDA) reports 72% of facilities manufacturing APIs for American drugs are overseas, with 13% in China. Download our white paper where we discuss effective strategies to secure and de-risk pharmaceutical supply chains and reveal how Curia assures the continual production of urgently needed drugs.

View resource 0088AE5F-29AA-4BF7-826D-52FA93D463D0

Ready to move from idea to impact?

Whether you have a question for our team or an opportunity you’re eager to pursue, one of our experts can help you get started.

Contact Us
More from Curia

040E93C7-D189-4233-A102-58C0580BE529 publications patents

Poster: In Vitro Characterization of a Dual Antagonistic Anti-LILRB2/LILRB4 Monoclonal Antibody

We have identified a dual antiLILRB2/LILRB4 antagonist. Targeting MDSCs with this antibody offers great promise for immunotherapy for cancer as well as its immense potential for synergy with PD-1 blockade.

icons/content-types/article article

Trends and Challenges in the Pharmaceutical Industry

Significant changes have taken place in the life sciences industry over the past few years. Since the Covid-19 pandemic, the U.S. government has urged biotech and pharmaceutical companies to increase domestic production in order to secure the drug su...